Maxwell Skor
Stock Analyst at Morgan Stanley
(4.20)
# 1,509
Out of 5,065 analysts
255
Total ratings
49.1%
Success rate
11.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Rated: Buy | $62 | $29.77 | +108.26% | 97 | Oct 19, 2026 | |
| ASND Ascendis Pharma | Rated: Buy | $273 | $229.95 | +18.72% | 34 | Oct 12, 2026 | |
| INSM Insmed | Reiterated: Buy | $218 | $95.29 | +128.78% | 32 | Oct 9, 2026 | |
| RARE Ultragenyx Pharmaceutical | Rated: Hold | $18 → $20 | $15.07 | +32.71% | 15 | Sep 21, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Hold | $60 | $50.04 | +19.90% | 3 | Aug 28, 2026 | |
| ADAG Adagene | Reiterated: Hold | n/a | $2.29 | - | 7 | Aug 17, 2026 | |
| BCYC Bicycle Therapeutics | Reiterated: Hold | n/a | $3.54 | - | 9 | Aug 17, 2026 | |
| MNPR Monopar Therapeutics | Rated: Buy | $115 → $130 | $71.47 | +81.89% | 4 | Aug 17, 2026 | |
| SANA Sana Biotechnology | Rated: Buy | $12 | $2.30 | +421.74% | 4 | Aug 17, 2026 | |
| TCRX TScan Therapeutics | Reiterated: Hold | n/a | $0.2102 | - | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $6.61 | +96.82% | 1 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $7 | $4.39 | +59.45% | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $103 | $62.65 | +64.41% | 21 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9.5 → $3.55 | $0.61 | n/a | 10 | Nov 20, 2024 |
Pharvaris
Oct 19, 2026
Rated: Buy
Price Target: $62
Current: $29.77
Upside: +108.26%
Ascendis Pharma
Oct 12, 2026
Rated: Buy
Price Target: $273
Current: $229.95
Upside: +18.72%
Insmed
Oct 9, 2026
Reiterated: Buy
Price Target: $218
Current: $95.29
Upside: +128.78%
Ultragenyx Pharmaceutical
Sep 21, 2026
Rated: Hold
Price Target: $18 → $20
Current: $15.07
Upside: +32.71%
CRISPR Therapeutics AG
Aug 28, 2026
Reiterated: Hold
Price Target: $60
Current: $50.04
Upside: +19.90%
Adagene
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.29
Upside: -
Bicycle Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.54
Upside: -
Monopar Therapeutics
Aug 17, 2026
Rated: Buy
Price Target: $115 → $130
Current: $71.47
Upside: +81.89%
Sana Biotechnology
Aug 17, 2026
Rated: Buy
Price Target: $12
Current: $2.30
Upside: +421.74%
TScan Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.2102
Upside: -
Aug 13, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $6.61
Upside: +96.82%
Aug 13, 2026
Rated: Hold
Price Target: $6 → $7
Current: $4.39
Upside: +59.45%
Jul 23, 2026
Rated: Buy
Price Target: $103
Current: $62.65
Upside: +64.41%
Nov 20, 2024
Reiterated: Buy
Price Target: $9.5 → $3.55
Current: $0.61
Upside: n/a